South Korea OKs First-in-Class Gene Therapy for Osteoarthritis
South Korea’s Ministry of Food and Drug Safety said today that it has approved the country’s first gene therapy for osteoarthritis, the lead product candidate of a Maryland-based regenerative medicine company.
Invossa-K Inj. was developed by Maryland-based TissueGene, whose Korean licensee, Kolon Life Sciences, won approval for the injectable treatment. According to the company, Invossa is a first-in-class cell-mediated gene therapy designed to treat moderate (Kellgren and Lawrence grade 3) knee osteoarthritis through regeneration of cartilage.
Invossa uses allogeneic human cartilage cells… Read more